17122-55-3

Basic information

• Product Name: N-(3-CHLORO-PHENYL)-2-[(E)-HYDROXYIMINO]-ACETAMIDE
• Synonyms: N-(3-CHLORO-PHENYL)-2-[(E)-HYDROXYIMINO]-ACETAMIDE
• CAS NO: 17122-55-3
• Molecular Formula: C₈H₇ClN₂O₂
• Molecular Weight: 198.60638
• Mol File: 17122-55-3.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• PKA: 8.67±0.10(Predicted)
• CAS DataBase Reference: N-(3-CHLORO-PHENYL)-2-[(E)-HYDROXYIMINO]-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-CHLORO-PHENYL)-2-[(E)-HYDROXYIMINO]-ACETAMIDE(17122-55-3)
• EPA Substance Registry System: N-(3-CHLORO-PHENYL)-2-[(E)-HYDROXYIMINO]-ACETAMIDE(17122-55-3)

Safety Data

• Hazardous Substances Data: 17122-55-3(Hazardous Substances Data)

Upstream product

• 302-17-0 chloral hydrate 
• 108-42-9 3-chloro-aniline 
• 141-85-5 3-chloroaniline hydrochloride 
• 75-87-6 chloral 

Downstream Products

• 1320362-02-4 4-chloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one 
• 1469872-14-7 2-(6-chloro-2,3-dioxoindolin-1-yl)-N-phenylacetamide 
• 56341-37-8 6-chloro-2-oxindole 
• 1261153-07-4 (E)-6-chloro-3-[[4-(methylsulfonyl)phenyl]methylene]indolin-2-one 
• 1261153-00-7 (E)-6-chloro-3-[[4-(sulfamoyl)phenyl]methylene]indolin-2-one 
• 130420-81-4 6-chloro-1-morpholinomethylisatin 
• 130420-80-3 4-chloro-1-morpholinomethylisatin 

Relevant articles and documents

Inhibitor of the human telomerase reverse trancriptase (hTERT) gene promoter induces cell apoptosis via a mitochondrial-dependent pathway

Telomerase is aberrantly expressed in many cancers and plays an important role in the development of cellular immortality and oncogenesis, which makes it a potential cancer therapeutic target for drug discovery. Here, we constructed a firefly luciferase r

Discovery of Isatin-Based Carbohydrazones as Potential Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase

Using ligand-based design strategy, a set of isatin-3-carbohydrazones was designed, synthesized and evaluated for dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibition properties. Compound 5-chloro-N′-(5-chloro-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 b) emerged as a potent MAGL inhibitor with nanomolar activity (IC50=3.33 nM), while compound 5-chloro-N′-(1-(4-fluorobenzyl)-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 j) was the most potent selective FAAH inhibitor (IC50=37 nM). Compound 5-chloro-N′-(6-chloro-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (13 c) showed dual FAAH-MAGL inhibitory activity with an IC50 of 31 and 29 nM respectively. Enzyme kinetics studies revealed that the isatin-based carbohydrazones are reversible inhibitors for both FAAH and MAGL. Further, blood-brain permeability assay confirmed that the lead compounds (13 b, 13 c, 13 g, 13 m and 13 q) are suitable as CNS candidates. Molecular dynamics simulation studies revealed the putative binding modes and key interactions of lead inhibitors within the enzyme active sites. The lead dual FAAH-MAGL inhibitor 13 c showed significant antioxidant activity and neuroprotection in the cell-based cytotoxicity assay. In summary, the study yielded three potent FAAH/MAGL inhibitor compounds (13 b, 13 c and 13 j) with acceptable pharmacokinetic profile and thus can be considered as promising candidates for treating neurological and mood disorders.

A Benzisoelenazolone modified pyrrole methyl ester substituted indole ketone compound and use thereof

The invention discloses a benzisoselenazolone-modified pyrrolyl formate-substituted indolone compound and a use thereof. The invention depends on and claims the priority of a Chinese patent application 201110105248.0 submitted on April 26, 2011. Through reference, all contents of the Chinese patent application 201110105248.0 are incorporated into the invention. The benzisoselenazolone-modified pyrrolyl formate-substituted indolone compound is shown in the general formula I. The 2-indolone compound provided by the invention has excellent antitumor activity and can be widely used for preparation of antitumor drugs.